By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom has filed a Form S-3 with the US Securities and Exchange Commission covering the potential sale of securities worth $150 million.

Under the shelf registration, Sequenom may from time to time offer up to $150 million of common stock, preferred stock, debt securities, and warrants in any combination. The firm said that it may sell the securities directly to investors or to or through agents, underwriters, or dealers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.